New Hope for Relapsing Multiple Sclerosis Novartis has recently announced significant findings from its Phase III clinical trials for remibrutinib, an investigational oral treatment for Relapsing Multiple Sclerosis (RMS). The data indicates that this therapy has successfully met its primary endpoints, offering a potential new avenue for patients managing this complex condition. Understanding the Clinical…